Analysis of the Treatment Efficacy in Late Diagnosis of Alport Syndrome in a Child: Clinical Case

Background. Alport syndrome is a systemic, hereditary, progressive disease characterized by ultrastructural changes in the glomerular basement membrane caused by pathogenic variants of type IV collagen genes. The use of angiotensin-converting enzyme inhibitors (ACEI) for nephroprotection is effective at the microhematuria and/or albuminuria stage. Treatment tactics in case of nephrotic syndrome development in such patients remains the subject of discussion. Clinical case description. The patient was diagnosed with proteinuria at the neonatal period and hematuria at the age of one month. The hereditary nephritis was diagnosed at the age of 6 years; the ACEI was administered, however, the proteinuria continued to increase. The diagnosis was confirmed at the age of 8.5 years via the puncture nephrobiopsy: collagenopathy, type IV, focal segmental glomerular sclerosis. Moreover, chronic bilateral sensorineural hearing loss and bilateral myopic astigmatism were diagnosed. Ciclosporin A (125 mg/day) was additionally prescribed. The increase in the cystatin C, urea, uric acid, cholesterol levels in blood was mentioned after 14 months of treatment. These parameters decreased after reducing cyclosporine A dose to 100 mg/day, however, proteinuria has increased. Angiotensin II receptor blocker (candesartan 8 mg/day) was prescribed to enhance nephroprotective therapy at the age of 10 years 2 months. Another increase of the immunodepressant dose was performed at the age of 11, it led to decrease in the estimated glomerular filtration rate and increase of creatinine, cystatin C, urea, cholesterol, uric acid, and potassium levels in the blood. These changes were considered as cyclosporine-dependent. The dose of cyclosporine A was reduced to 125 mg/day, and to 100 mg/day from the age of 14. There was no progression of chronic kidney disease at the follow-up at the age of 15.5 years. Conclusion. Nephroprotective treatment of a child with Alport syndrome initiated after the development of nephrotic syndrome did not stop the chronic kidney disease progression. Whereas relatively high doses of ciclosporin A have reduced proteinuria but led to nephrotoxicity and cyclosporin dependence.

1. Ignatova MS, Dlin VV. Hereditary kidney diseases running with hematuria. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2014;59(3):82–90. (In Russ).

2. Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58(3):925–943. doi: https://doi.org/10.1046/j.1523-1755.2000.00250.x

3. Pajari H, Kääriäinen H, Muhonen T, Koskimies O. Alport’s syndrome in 78 patients: epidemiological and clinical study. Acta Paediatr. 1996;85(11):1300–1306. doi: https://doi.org/10.1111/j.1651-2227.1996.tb13915.x

4. Ignatova MS, Lebedenkova MV, Dlin VV, et al. Chronic kidney diseases: pediatric point of view. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2008;53(6):4–10. (In Russ).

5. Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol. 2001;12(1):97–106. doi: https://doi.org/10.1681/ASN.V12197

6. Boye E, Mollet G, Forestier L, et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet. 1998;63(5):1329–1340. doi: https://doi.org/10.1086/302106

7. Knebelmann B, Breillat C, Forestier L, et al. Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome. Am J Hum Genet. 1996;59(6):1221–1232.

8. Savige J, Sheth S, Leys A, et al. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol. 2015;10(4):703–709. doi: https://doi.org/10.2215/CJN.10581014

9. Kashtan CE. Alport Syndrome: Achieving Early Diagnosis and Treatment. Am J Kidney Dis. 2021;77(2):272–279. doi: https://doi.org/10.1053/j.ajkd.2020.03.026

10. Gregorio V, Caparali EB, Shojaei F, et al. Alport Syndrome: Clinical Spectrum and Therapeutic Advances. Review. Kidney Med. 2023;5(5):100631. doi: https://doi.org/10.1016/j.xkme.2023.100631

11. Aksenova ME, Konkova NE, Tutelman KM. Blood pressure level and progression of renal disease in children with Х-linked Alport syndrome. Nephrology (Saint-Petersburg). 2020;24(6):78–84. (In Russ). doi: https://doi.org/10.36485/1561-6274-2020-24-6-78-84

12. Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81(5):494–501. doi: https://doi.org/10.1038/ki.2011.407

13. Gross O, Tönshoff B, Weber LT, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int. 2020;97(6):1275–1286. doi: https://doi.org/10.1016/j.kint.2019.12.015

14. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults — an update for 2020. Pediatr Nephrol. 2021;36(3):711–719. doi: https://doi.org/10.1007/s00467-020-04819-6

15. Mastrangelo A, Brambilla M, Romano G, et al. Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease. J Clin Med. 2021;10(21):4946. doi: https://doi.org/10.3390/jcm10214946

16. Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int. 1999;55(3):1051–1056. doi: https://doi.org/10.1046/j.1523-1755.1999.0550031051.x

17. Massella L, Muda AO, Legato A, et al. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol. 2010;25(7):1269–1275. doi: https://doi.org/10.1007/s00467-010-1484-3

18. Sugimoto K, Fujita S, Miyazawa T, et al. Cyclosporin A may cause injury to undifferentiated glomeruli persisting in patients with Alport syndrome. Clin Exp Nephrol. 2014;18(3):492–498. doi: https://doi.org/10.1007/s10157-013-0836-2

19. Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57–63. doi: https://doi.org/10.1007/s00467-006-0227-y

20. Khronicheskaya bolezn’ pochek (u detei): Clinical guidelines. Moscow; 2022. 129 p. (In Russ).

21. Gematuriya u detei: Clinical guidelines. Moscow; 2016. 30 p. (In Russ).

22. Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–375. doi: https://doi.org/10.1681/ASN.2012020148J

23. Warady BA, Agarwal R, Bangalore S, et al. Alport Syndrome Classification and Management. Kidney Med. 2020;2(5):639–649. doi: https://doi.org/10.1016/j.xkme.2020.05.014

24. Groznova OS, Dlin VV, Shagam LI, et al. Gender characteristics of the clinical manifestations of cardiovascular system involvement in X-linked Alport syndrome. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2016;61(3):76–80. (In Russ). doi: https://doi.org/10.21508/1027–4065–2016–61–3–76–80

25. Guidelines of the Russian Scientific Medical Society of Internal Medicine on the diagnosis, treatment and rehabilitation of patients with the connective tissue dysplasia (first edition). Medical News of North Caucasus. 2018;13(1.2):137–209. (In Russ). doi: https://doi.org/10.14300/mnnc.2018.13037

26. Aksenova ME. Alport syndrome: our knowledge update. Nephrology (Saint-Petersburg). 2021;25(3):75–83. (In Russ). doi: https://doi.org/10.36485/1561-6274-2021-25-3-75-83

27. Boeckhaus J, Strenzke N, Storz C, et al. Characterization of Sensorineural Hearing Loss in Children with Alport Syndrome. Life (Basel). 2020;10(12):360. doi: https://doi.org/10.3390/life10120360

28. Nishiori H, Sakata T, Makino SI, et al. Alport syndrome: A case study of chronic type A aortic dissection. J Card Surg. 2022;37(7):2134–2137. doi: https://doi.org/10.1111/jocs.16496

29. Kamiar A, Alitter Q, Capcha JMC, et al. Ascending aortic aneurysm and histopathology in Alport syndrome: a case report. BMC Nephrol. 2023;24(1):300. doi: https://doi.org/10.1186/s12882-023-03345-5

30. Alport Syndrome Collaborative Group; National Clinical Research Center of Kidney Diseases; Rare Diseases Branch of Beijing Medical Association. Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023). Zhonghua Yi Xue Za Zhi. 2023;103(20):1507–1525. doi: https://doi.org/10.3760/cma.j.cn112137-20230203-00161

31. Gross O, Perin L, Deltas C. Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol Dial Transplant. 2014;29 (Suppl 4):iv124–iv130. doi: https://doi.org/10.1093/ndt/gfu028

32. Guney I, Selcuk NY, Altintepe L, et al. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail. 2009;31(9):779–784. doi: https://doi.org/10.3109/08860220903150312

33. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93(5):1045–1051. doi: https://doi.org/10.1016/j.kint.2017.12.018

34. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9): 486–492. doi: https://doi.org/10.1038/ncpneph0575

35. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16(9 Pt 1):781–788. doi: https://doi.org/10.1016/s0895-7061(03)00913-0

36. Nefroticheskii sindrom u detei: Clinical guidelines. Moscow; 2016. 31 p. (In Russ).

37. Nikitin AV. Mechanisms of Nephrotoxic Action of Immunodepressants, Calcineurine Inhibitors. Antibiotics and Chemotherapy. 2014; 59(1-2):44–47. (In Russ).